Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Avacta Group (LSE:AVCT) Remains a Closely Watched Biotech in the FTSE AIM All Share Index

Avacta is a clinical-stage biopharmaceutical business focused on oncology. Its central technology is the preCISION platform, which is designed to keep a chemotherapy payload largely inactive in the bloodstream and to release it preferentially in the tumour microenvironment. The idea is that, by concentrating …

Ankur Sharma | 19 October 2026

What IXICO (LSE: IXI) brings to the FTSE AIM All Share Index healthcare technology mix

IXICO provides neuroimaging analysis services, primarily to pharmaceutical and biotechnology companies running clinical trials in neurological diseases. It analyses brain scans, such as MRI and PET images, to generate data that helps trial sponsors measure how a disease progresses and whether a therapy is …

Ishan Mudgal | 19 October 2026

How Kooth (LSE: KOO) is positioned in digital mental health within the FTSE AIM All Share Index

Kooth provides online mental health and wellbeing support, primarily for children and young people. Its services are typically free at the point of use for the people who access them and are funded by public bodies, such as NHS commissioners and local authorities in …

Ishan Mudgal | 19 October 2026

Why Advanced Medical Solutions (LSE:AMS) stands out in the FTSE AIM All Share Index healthcare cohort

Advanced Medical Solutions, often referred to as AMS, is a UK-based developer and manufacturer of products for the surgical and wound care markets. Its surgical portfolio includes tissue adhesives sold under the LiquiBand brand, which are used to close wounds and surgical incisions, alongside …

Ankur Sharma | 19 October 2026

How AOTI (LSE:AOTI) Fits Into the FTSE AIM All Share Index as a Wound Care Technology Story

AOTI develops and sells a home-based therapy for chronic wounds that uses topically applied oxygen. Its system, marketed under the TWO2 name, delivers cyclical pressurised oxygen directly to a wound through a single-use device that patients can use at home. The company has focused …

Ankur Sharma | 19 October 2026

What Aptamer Group (LSE:APTA) brings to life sciences on the FTSE AIM All Share Index

Aptamer Group develops aptamers, short strands of nucleic acid that can be designed to bind tightly and selectively to a chosen target, in a way that is broadly comparable to antibodies. The company markets its binders under the Optimer brand and positions them as …

Ankur Sharma | 19 October 2026

What 4basebio (LSE:4BB) is aiming to do in synthetic DNA as a FTSE AIM All Share Index constituent

4basebio develops and manufactures synthetic DNA products intended for use in gene therapies, mRNA medicines, DNA vaccines and gene editing. Traditionally, much of the DNA used in these fields has been produced in bacteria as plasmids, a process that can be slow and may …

Ankur Sharma | 19 October 2026

How Abingdon Health (LSE:ABDX) fits into the diagnostics segment of the FTSE AIM All Share Index

Abingdon Health is a UK-based diagnostics company specialising in lateral flow tests, the format familiar to many people from home pregnancy and rapid antigen tests. Headquartered in Yorkshire, it operates largely as a contract development and manufacturing organisation, helping other companies design, develop, scale …

Ankur Sharma | 19 October 2026

What investors should know about genedrive (LSE: GDR) and its place in the FTSE AIM All Share Index

genedrive is a UK molecular diagnostics developer based in Manchester. Its approach centres on compact, rapid genetic tests designed to be used close to the patient, such as on a hospital ward, rather than requiring samples to be sent to a central laboratory. Its …

Ishan Mudgal | 19 October 2026

Why GENinCode (LSE: GENI) is a niche cardiovascular genomics play on the FTSE AIM All Share Index

GENinCode develops genetic tests designed to help assess an individual's risk of cardiovascular disease, the leading cause of death worldwide. Its products combine genetic information with clinical risk factors to produce a more personalised view of a patient's risk than traditional scoring systems alone. …

Ishan Mudgal | 19 October 2026
Support

Hi! How can we help you today?

Loading…